Skip to content

US · MED · SPECIALTY BUSINESS SERVICES

Medifast, Inc. (MED) intrinsic value and stock valuation

$11.75as of 2026-11-21 · Mkt cap 136.54M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medifast, Inc. DCF and intrinsic value

InvestorsCraft values MED with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MED’s statements →

Medifast, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Industrials · Specialty Business Services Baltimore, MD 21224 medifastinc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$385.8M-16.2% 5y CAGRd
20112025
Net income
-$-18.67M
20112025
Free cash flow
$1.25M-61% 5y CAGRd
20112025
Total equity
$198.9M+4.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$385.8M$602.5M$1.07B$1.6B$1.53B
Operating income-$-14.21M$2.88M$126.4M$184.8M$216.2M
Net income-$-18.67M$2.09M$99.4M$143.6M$164M
EPSd-$-1.7M$190.7K$9.1M$12.7M$13.9M
Operating cash flow$6.86M$24.5M$147.7M$194.6M$94.6M
Capital expenditure-$-5.61M-$-7.45M-$-6.48M-$-16.68M-$-34.21M
Free cash flow$1.25M$17M$141.2M$177.9M$60.3M
Total assets$257M$284.2M$309.9M$316.2M$398.3M
Total debt$16.8M$16.1M$22M$26.1M$32.5M
Net debt-$-72.52M-$-74.8M-$-72.43M-$-61.64M-$-71.64M
Total equity$198.9M$210.1M$201.5M$155M$202.5M
Cash and short-term investments$167.3M$162.3M$150M$87.7M$109.5M
Income statement
20252024202320222021
Revenue$385.8M$602.5M$1.07B$1.6B$1.53B
Cost of revenue$110.6M$157.8M$296.2M$458.2M$398.5M
Gross profit$275.2M$444.6M$775.9M$1.14B$1.13B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$289.4M$441.8M$649.5M$955.6M$911.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$289.4M$441.8M$649.5M$955.6M$911.4M
Cost and expenses$400M$599.6M$945.7M$1.41B$1.31B
Interest income$5.52M$4.8M$2.49M$0.00$0.00
Interest expense$0.00$0.00$0.00$700K$230K
Depreciation and amortization$10.5M$12.7M$13.1M$11M$6.81M
Ebitda$4.86M$16.5M$141.9M$195.7M$222.9M
Operating income-$-14.21M$2.88M$126.4M$184.8M$216.2M
Total other income/expenses, net$8.57M$910K$2.4M-$-750K-$-110K
Income before tax-$-5.64M$3.79M$128.8M$184.1M$216.1M
Income tax expense$13M$1.7M$29.4M$40.5M$52.1M
Net income-$-18.67M$2.09M$99.4M$143.6M$164M
Weighted average shares outstanding$11M$10.9M$10.9M$11.2M$11.7M
Weighted average diluted shares outstanding$11M$11M$10.9M$11.3M$11.8M
Balance sheet
20252024202320222021
Cash and short-term investments$167.3M$162.3M$150M$87.7M$109.5M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$20.2M$42.4M$54.6M$118.9M$180M
Total current assets$201.7M$214.4M$224M$222.8M$306.9M
Property, plant and equipment, net$38.5M$48.7M$67.1M$75.6M$80.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$55.3M$69.8M$85.9M$93.4M$91.5M
Total assets$257M$284.2M$309.9M$316.2M$398.3M
Accounts payable$15.1M$23.1M$39.2M$53.1M$70.9M
Short-term debt$4.6M$6.18M$5.88M$5.78M$6.52M
Deferred revenue$380K$320K$570K$7.36M$8.05M
Total current liabilities$43M$64.2M$92.3M$140.9M$169.8M
Long-term debt$12.2M$9.94M$16.1M$20.3M$26M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15.1M$9.94M$16.1M$20.3M$26M
Capital lease obligations$6.09M$16.1M$22M$26.1M$32.5M
Total liabilities$58.1M$74.1M$108.4M$161.2M$195.9M
Common stock$10K$10K$10K$10K$10K
Retained earnings$158.3M$176.8M$174.7M$139.9M$190.3M
Accumulated other comprehensive income (loss)$230K$180K$250K$20K$110K
Total equity$198.9M$210.1M$201.5M$155M$202.5M
Total investments$78M$71.4M$55.6M$0.00$5.36M
Total debt$16.8M$16.1M$22M$26.1M$32.5M
Net debt-$-72.52M-$-74.8M-$-72.43M-$-61.64M-$-71.64M
Cash flow statement
20252024202320222021
Net income-$-18.67M$2.09M$99.4M$143.6M$164M
Depreciation and amortization$14.2M$17.4M$13.1M$11M$6.81M
Stock-based compensation$7.64M$7.36M$8.19M$11.1M$9.9M
Change in working capital-$-9.8M-$-9.74M$20.3M$21.7M-$-87.65M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$22.2M$12.2M$64.3M$61.2M-$-126.65M
Accounts payable-$-23.91M-$-34.99M-$-35.71M-$-37.59M$0.00
Net cash provided by operating activities$6.86M$24.5M$147.7M$194.6M$94.6M
Investments in property, plant and equipment-$-5.61M-$-7.45M-$-6.48M-$-16.68M-$-34.21M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-7.93M-$-26.52M-$-61.05M-$-11.41M-$-29.06M
Common stock issued$0.00$0.00$0.00$0.00$810K
Common stock repurchased-$-370K-$-840K-$-6.96M-$-127.96M-$-62.09M
Dividends paid-$-200K-$-710K-$-73.02M-$-71.62M-$-63.86M
Net cash used for financing activities-$-560K-$-1.51M-$-79.79M-$-199.58M-$-125.13M
Net change in cash-$-1.62M-$-3.51M$6.75M-$-16.49M-$-59.54M
Cash at end of period$89.3M$90.9M$94.4M$87.7M$104.2M
Operating cash flow$6.86M$24.5M$147.7M$194.6M$94.6M
Capital expenditure-$-5.61M-$-7.45M-$-6.48M-$-16.68M-$-34.21M
Free cash flow$1.25M$17M$141.2M$177.9M$60.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medifast, Inc.

        Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.

        CEO
        Nicholas Johnson
        Employees
        380
        Beta
        0.68

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Medifast, Inc. (MED)?

        Medifast, Inc. (MED) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MED undervalued?

        MED trades at a price of $11.75 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.